The last few decades have been revolutionary in terms of improving end stage kidney disease (ESKD) care with respect to increasing the number of transplant recipients as well as upping the immunosuppression game. The use of calcineurin inhibitors…
The ELITE-Symphony study enshrined standard triple therapy immunosuppression of tacrolimus, mycophenolic acid and prednisolone, for renal transplant recipients. We get familiar with these agents relatively quickly in our renal training, but what about the other less common agents…
This is a really exciting bracket and is full of new agents that will hopefully lead to major advances in our field. Acthar is the outlier here as, even though it is a peptide, it is not an…
